Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel

Pharmacotherapy

Volumn 32, Issue 4, 2012, Pages 323-332

  Reese, Emily S ^a   Mullins, C Daniel ^a   Beitelshees, Amber L ^b   Onukwugha, Eberechukwu ^a  

^a School of Pharmacy   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clopidogrel; Cost effectiveness; Cytochrome P450 2C19; Pharmacogenomics; Prasugrel

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; GENERIC DRUG; PRASUGREL; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SELECTIVITY; GENETIC SCREENING; GENOTYPE; GENOTYPING TECHNIQUE; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHARMACOGENOMICS; SENSITIVITY ANALYSIS; STROKE; TREATMENT DURATION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; FIBRINOLYTIC THERAPY; GENETICS; STATISTICAL MODEL;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; DRUGS, GENERIC; GENOTYPE; HEMORRHAGE; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 84864101032     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01048     Document Type: Article

References (38)

1. Sanofi. PLAVIX® (clopidogrel bisulfate) tablets Prescribing Information. Available from http://products.sanofi.us/PLAVIX/PLAVIX.html. Accessed March 16, 2011.
2. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2010. Available at http://www.imshealth.com/ deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/ IHII-UseOfMed-report.pdf. Accessed February 9, 2012.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
4. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60.
5. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36.
6. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-11.
7. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236-42.
8. Giusti B, Gori AM, Marcucci R, Abbate R. Research highlights: CYP2C19 genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy? Future Med 2009;10:1131-3.
9. Shuldiner A, O'Connell J, Bliden K, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57.
10. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32.
11. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-35.
12. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
13. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7.
14. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010;8:1678-84.
15. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrelthrombolysis in myocardial infarction TRITON-TIMI 38. Circulation 2010;121:71-9.
16. Greenhalgh J, Bagust A, Boland A, et al. Prasugrel for the treatment of acute cornary artery syndromes with percutaneous cornary intervention. Health Technol Assess 2010;14:31-8.
17. Genelex. CYP2C19 Genotyping: Pharmacogenetic Testing. Available from http://www.healthanddna.com/healthcare-professional/p450-2c19-genotyping.html. Accessed March 16, 2011.
18. Centers for Medicare and Medicaid Services. Fee Schedule Clinical Laboratory Fee Schedule. Available from http://www. cms.gov/ClinicalLabFeesched/ 02-clinlab.asp. Accessed March 16, 2011.
19. Jacobson KM, Hall Long K, McMurtry EK, Naessens JM, Rihal CS. The economic burden of complications during percutaneous coronary intervention. Qual Saf Health Care 2007;16:154-9.
20. PDR Staff, eds. Red book: pharmacy's fundamental reference. Montvale, NJ: Thomson Reuters, 2010.
21. Ewen EF, Zhao L, Kolm P, et al. Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol 2009;22:266-73.
22. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9.
23. United States Bureau of Labor and Statistics. How BLS measures price change for Medical Care Services in the Consumer Price Index. Available from http://www.bls.gov/cpi/cpifact4. htm. Accessed March 16, 2011.
24. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the american college of cardiology foundation task force on clinical expert consensus documents and the american heart association endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol 2010;56:321-41.
25. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
27. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-34.
28. Pride YB, Wiviott SD, Buros JL, et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in myocardial infarction (TIMI) 38 substudy. Am Heart J 2009;158:e21-6.
29. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-Treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-Analysis. J Am Coll Cardiol 2010;56:134-43.
30. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-Analysis. JAMA 2010;304:1821-30.
31. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006;6:52.
32. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010;55:2813-5.
33. Centers for Medicare and Medicaid Services. Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N). Available from https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx? NCAId=224 &ver=15&NcaName=Pharmacogenomic+Testing+for+Warfarin +Response&NCDId=333&ncdver=1&IsPopup=y&bc= AAAAAAAAIAAA&. Accessed October 6, 2011.
34. Aetna. Pharmacogenetic and Pharmacodynamic Testing. Available from http://www.aetna.com/cpb/medical/data/700-799/0715. html. Accessed September 22, 2011.
35. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.
36. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
37. Daiichi Sankyo and Lily. Daiichi Sankyo and Lilly. Important safety information-Effient.com (prasugrel) tablets. Available from http://www.effient. com/Pages/important-safety-information. aspx. Accessed March 16, 2011.
38. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable Angina/Non-ST- elevation myocardial infarction (updating the 2007 guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in collaboration with the American college of emergency physicians, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 2011;57:1959.